Innovative Targeted and Immune-Mediated Cancer Therapies
Pipeline
Developing first-in-class small molecule product candidates with broad potential benefit to patients
Science
Modulating validated and new pathways to develop novel therapeutics
News
September 20,
2021
Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche
September 13,
2021
Tempest Enters into Exclusive License Agreement with the University of California for Novel Cancer Target
September 9,
2021
Tempest to Present at Upcoming Investor Conferences
Events
Wednesday,
September 22ND,
2021
at
9:55 AM
Eastern
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Monday,
September 13TH,
2021
at
7:00 AM
Eastern
H.C. Wainwright 23rd Annual Global Investment Conference
Listen: Webcast
Monday,
March 29TH,
2021
at
8:30 AM
Eastern
Tempest and Millendo Proposed Merger Investor Call
Listen: Webcast
Download: Proposed Merger of Tempest and Millendo [pdf]